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Abstract
Imerslund-Gräsbeck syndrome (IGS) or selective vitamin B12 (cobalamin) malabsorption with
proteinuria is a rare autosomal recessive disorder characterized by vitamin B12  deficiency
commonly resulting in megaloblastic anemia, which is responsive to parenteral vitamin B12 therapy
and appears in childhood. Other manifestations include failure to thrive and grow, infections and
neurological damage. Mild proteinuria (with no signs of kidney disease) is present in about half of
the patients. Anatomical anomalies in the urinary tract were observed in some Norwegian patients.
Vitamin B12 absorption tests show low absorption, not corrected by administration of intrinsic
factor. The symptoms appear from 4 months (not immediately after birth as in transcobalamin
deficiency) up to several years after birth. The syndrome was first described in Finland and Norway
where the prevalence is about 1:200,000. The cause is a defect in the receptor of the vitamin B12-
intrinsic factor complex of the ileal enterocyte. In most cases, the molecular basis of the selective
malabsorption and proteinuria involves a mutation in one of two genes, cubilin (CUBN) on
chromosome 10 or amnionless (AMN) on chromosome 14. Both proteins are components of the
intestinal receptor for the vitamin B12-intrinsic factor complex and the receptor mediating the
tubular reabsorption of protein from the primary urine. Management includes life-long vitamin B12
injections, and with this regimen, the patients stay healthy for decades. However, the proteinuria
persists. In diagnosing this disease, it is important to be aware that cobalamin deficiency affects
enterocyte function; therefore, all tests suggesting general and cobalamin malabsorption should be
repeated after abolishment of the deficiency.
Disease name/synonyms
Enterocyte cobalamin malabsorption – Enterocyte intrin-
sic factor receptor, defect of - Gräsbeck-Imerslund disease
– Imerslund-Gräsbeck syndrome (or disease) – Megalob-
lastic anemia 1 – Selective vitamin B12 malabsorption
with proteinuria.
Nowadays the most frequently used name is Imerslund-
Gräsbeck syndrome, abbreviated to IGS.
Definition
The Imerslund-Gräsbeck syndrome (IGS) is a rare auto-
somal recessive disorder characterized by vitamin B12
(cobalamin) deficiency due to selective malabsorption of
this vitamin and usually resulting in megaloblastic ane-
mia appearing in childhood (but not immediately after
birth) and which is responsive to parenteral vitamin B12
therapy. Mild proteinuria is frequently but not always
present. Neurological symptoms typical of cobalamin
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deficiency have been reported [1] but are seldom pro-
nounced.
Epidemiology
To date, 27 patients from 19 families in Finland (popula-
tion 5.2 million) and 19 from 15 families in Norway
(population 4.6 million) have been reported (unpub-
lished data and Dr. H. Broch, personal communication
from). This gives an estimated prevalence of
<6:1,000,000. About 300 cases have been published
worldwide, with new cases predominantly appearing in
eastern Mediterranean countries. However, many cases
may be misdiagnosed.
Clinical description
Patient age at diagnosis varies from a few months to about
fourteen years old. Patients usually present with non-spe-
cific health problems such as failure to grow and thrive,
recurrent gastrointestinal or respiratory infections, pallor
and fatigue. Detailed examination reveals anemia and/or
proteinuria. Typical features of megaloblastic anemia may
be observed together with neurological signs, which have
been reported as mild in the published cases. Close rela-
tives may show similar clinical manifestations.
Megaloblastic anemia is caused by inability of the hemat-
opoietic cells to divide, due to failure of DNA replication.
All dividing cells are affected, especially rapidly replicating
ones, such as mucosal and sperm cells [2]. In principle,
anemia is not an obligatory sign of cobalamin deficiency,
which may manifest itself as a purely neurological disease
and possibly in other ways (protracted infections, ambly-
opia, etc.). Also, there is increasing evidence that subclini-
cal deficiency of cobalamin contributes to the
development of atherosclerosis, dementia and osteoporo-
sis especially in the aged patients [3-5]. However, accord-
ing to the author's experience, most cases of IGS present
with typical megaloblastic anemia, perhaps with the
exception of patients detected by examining the relatives
of diagnosed cases.
Proteinuria often, but not always, accompanies IGS. A
study of 13 Finnish patients found that moderate or
clearly evident proteinuria was present in six of the sub-
jects. The proteinuria was neither typically glomerular nor
tubular [6]. Similar findings were obtained in a Norwe-
gian study [7]. Both studies indicated that in properly
treated patients, the proteinuria persisted over the years
without noticeable change and that kidney function did
not deteriorate. In some of the original Norwegian cases,
congenital abnormalities of the urinary tract (double ure-
ters, horseshoe kidney) were found [8], but in recently
diagnosed cases such anomalies have been absent (H.
Brock, personal communication).
Association of IGS with a number of congenital diseases
and anomalies has been reported (beta-thalassemia, doli-
cocephaly, chromosomal deletion) but they appear not to
be linked to this condition [9].
Etiology
Physiology of vitamin B12 transport
The intestinal absorption of cobalamin involves a number
of steps and a disturbance in any of them may cause
cobalamin malabsorption resulting in cobalamin defi-
ciency. Under physiological conditions, the vitamin is lib-
erated from food by digestive enzymes and subsequently
becomes bound to the glycoprotein haptocorrin (also
called R-protein or cobalophilin), which is present in leu-
kocytes, saliva and other secretions. In the small intestine,
the change in pH and action of pancreatic enzymes result
in vitamin dissociation from haptocorrin. The vitamin is
then available for binding to the intrinsic factor secreted
by the gastric mucosa. The resulting cobalamin-intrinsic
factor complex attaches to a receptor in the distal small
intestine (ileum) in the presence of calcium ions. Subse-
quently, the complex is internalized, the vitamin liberated
and transferred to transcobalamin (also called transco-
balamin II) synthesized in the intestine (probably in the
vascular endothelium) and elsewhere. From the blood the
transcobalamin-cobalamin complex delivers the vitamin
to the tissues by attaching to specific receptors. Lack of
transcobalamin results in rapid development of megalob-
lastic anemia after birth and also failure to absorb cobala-
min from the intestine [10,11]. Some steps in the
transport of the vitamin across the intestine may still not
be understood [12].
Pathophysiology of vitamin B12 transport and genetics
IGS is caused by a selective incapacity to transport vitamin
B12 across the intestinal wall, and is not related to a lack of
gastric intrinsic factor. Theoretically, a similar condition
could be caused by malfunction of any component in the
process transferring the vitamin bound to intrinsic factor
in the lumen of the distal small intestine to the specific
cobalamin carrier in the blood, transcobalamin. The
name "Selective vitamin B12  malabsorption with pro-
teinuria" was used to describe the condition when it was
reported in Finland in 1960 [13]. A very similar condition
was described simultaneously in Norway by Olga Imers-
lund [8] under the name "Idiopathic chronic megaloblas-
tic anemia in children". Five of the 10 Norwegian cases
had congenital abnormalities of the urinary tract. Absorp-
tion tests with radioactive vitamin B12 later demonstrated
that the basic error in these cases was also a specific
cobalamin absorption defect [14]. However, a recent
study of both populations [15] identified mutations in
two different genes: the cubilin (CUBN) gene in the Finn-
ish families (three mutations) and the amnionless (AMN)
gene in the Norwegian families (two mutations). In Tur-Orphanet Journal of Rare Diseases 2006, 1:17 http://www.OJRD.com/content/1/1/17
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key, Israel and Saudi Arabia two different AMN mutations
and three different CUBN  mutations have been found
[15]. It was concluded that the Scandinavian cases result
from enrichment of founder mutations, whereas in the
Mediterranean region the high degree of consanguinity
leads to offspring with rare mutations in both genes.
CUBN and AMN encode the two subunits (cubilin and
amnionless) of the cobalamin-intrinsic factor receptor of
the ileal mucosa [15]. The CUBN gene is located on chro-
mosome 10 and AMN on chromosome 14 [16]. The gene
map loci are 10p12.1 [17,18] and 14q32 [16], respec-
tively. The cubilin-amnionless complex is called cubam
and is considered to be essential for intestinal cobalamin
uptake, renal protein reabsorption and early rodent
embryogenesis. Amnionless is thought to bind to the
amino-terminal region of cubilin and to direct the subcel-
lular localization and endocytosis of cubilin with its lig-
and. Biallelic mutations affecting either of the two
proteins result in IGS in men and dogs [19].
Recent studies aimed at identifying the causative genes
and molecules in suspected cases of IGS, revealed defects
in the gastric intrinsic factor gene (GIF). Thus, these cases
cannot be classified as IGS [20] and correspond to other
vitamin B12  deficiency syndromes, notably pernicious
anemia. Evidently, many of the published cases of IGS
may not be correctly diagnosed.
Phenotype-genotype correlations
Congenital anomalies were rare in the Finnish patients
carrying the CUBN mutation but urinary tract anomalies
were observed in the Norwegian patients carrying the
AMN mutation. This is not surprising given that studies in
mice have shown that amnionless is essential for gastrula-
tion [21].
Environmental factors
In 1995 it was noted that after the initial reports, few new
cases of IGS appeared. One explanation for this could be
a change in environmental factors, such as the diet [17].
However, during the last decade the author has seen new
Finnish cases appear at approximately the rate expected
from the prevalence estimate (see the Epidemiology sec-
tion).
Animal model
IGS has been found in dogs, first in Giant Schnautzers
[22]. He et al. [23] demonstrated a linkage of canine IGS
to chromosome 8 in a region orthologous to human chro-
mosome 14q32.2-ter, in an interval that contains the
AMN gene. Further studies showed that effective cubam
expression does not occur in the absence of amnionless.
Cubilin and amnionless thus belong to the group of
membrane receptors that rely on the accessory activity of
a separate gene product for trafficking and membrane
expression [24].
Diagnosis and differential diagnosis
In practice, the clinical starting point is detection of mac-
rocytic and/or megaloblastic anemia and possibly pro-
teinuria when a child in a generally poor condition is
subjected to laboratory tests. A number of pathogenetic
factors and mechanisms may cause the anemia, but the
predominant causes are deficiencies of folate and cobala-
min. Lack of folate is common in developing countries
but rare in the Western world, except among socio-eco-
nomically disadvantaged groups, in non-breast-fed or
chronically ill children and in those suffering from celiac
disease. Cobalamin deficiency usually causes some neuro-
logical or psychiatric symptoms. A number of laboratory
tests are helpful in diagnosing and differentiating between
folate and vitamin B12 deficiency. They will be discussed
in the next section, however, none of them can be
regarded as the "gold standard". Diagnosis ex juvantibus
may be reached by observing a clear-cut response to treat-
ment with small oral doses of folate (the dose should not
exceed a few micrograms as larger doses may cause neuro-
logical damage in patients with cobalamin deficiency) or
vitamin B12 injection. When the presence of vitamin B12
deficiency has been established, the next step is to deter-
mine its cause.
There are several major causes of vitamin B12 deficiency.
Exposure to nitrous oxide causes cobalamin deficiency by
destroying the cobalamin coenzymes. As plants are lack-
ing in vitamin B12, a totally vegetarian diet may cause
cobalamin deficiency, but because of high folate intake,
the signs tend to be more neurological than hematologi-
cal. Cobalamin deficiency has consequently been found
in babies of nursing mothers that abuse laughing gas
(nitrous oxide) or are Vegans. In some countries, these
may be the most common causes of cobalamin deficiency
in babies. A usual cause of cobalamin deficiency is poor
absorption of vitamin B12. Consequently, gastrointestinal
morphology and function need to be examined, including
the use of tests for general and cobalamin absorption. Rel-
atively specific cobalamin malabsorption may occur in
some cases of general malabsorption (celiac disease or
tropical sprue) or due to a pathological intestinal flora in
connection with intestinal blind-loops or diverticulosis.
Fish tapeworm infection is known to cause cobalamin
deficiency in children. Though rare, genuine pernicious
anemia also occurs in children and it is caused by intrinsic
factor deficiency due to atrophic gastritis. Intrinsic factor
may also be congenitally lacking or misassembled. A
recent study reported that IGS is difficult to distinguish
from cases caused by mutations in the GIF (gastric intrin-
sic factor) gene [20]; however, these difficulties can prob-
ably be explained by radiocobalamin absorption testsOrphanet Journal of Rare Diseases 2006, 1:17 http://www.OJRD.com/content/1/1/17
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having been performed during the deficiency state or not
at all (see below). Transcobalamin deficiency and errors
in the biosynthesis of cobalamin coenzymes result in
severe illness shortly after birth.
Summary of diagnostic steps
In conclusion, the diagnosis of IGS is reached by first
detecting the presence of cobalamin deficiency, then dem-
onstrating that this vitamin is poorly absorbed, then
excluding other known causes of vitamin B12 malabsorp-
tion and finally, by showing that after correction of the
deficiency state, the only nutrient to be poorly absorbed is
vitamin B12. Benign and therapy-resistant proteinuria is a
helpful, but not an obligatory sign of IGS. Another
approach is mutational analysis of the genes concerned
(see below).
Diagnostic methods
Macrocytic and megaloblastic anemias are diagnosed by
analysis of peripheral blood and bone marrow, which
reveals low hemoglobin, pancytopenia, increased red cell
size objectively indicated by high mean corpuscular
hemoglobin (MCH) and mean corpuscular volume
(MCV) indexes, and typical morphological changes in
both red and white cells and platelets and their precursors,
e.g. megaloblasts, granulocytes with polylobulated nuclei,
etc. [25]. The myelogram helps to rule out malignant and
other conditions that may resemble megaloblastic ane-
mia.
As stated, the main causes of megaloblastic anemia are
lack of folate or cobalamin. Rare causes include congeni-
tal disturbances in nucleic acid metabolism (e.g. orotic
aciduria) and lack of other B vitamins. Assay of total
serum cobalamin and folate often differentiates between
the two deficiencies. Also, a therapeutic test with cobala-
min or a few micrograms of folate is helpful. A clear-cut
positive response (i.e. reticulocytosis, rise in the concen-
tration of blood cells and improved neurological and gen-
eral condition) is diagnostic.
Although numerous more advanced tests for diagnosis of
vitamin B12 deficiency exist [26,27], there is no consensus
as to which one is the best. Commonly used tests are
determination of the serum total vitamin B12 or transco-
balamin-bound vitamin (holo-transcobalamin) concen-
trations. Measurements of the metabolites
methylmalonate and homocysteine are also used. In prin-
ciple, methylmalonate accumulates in cobalamin defi-
ciency but not in lack of folate.
The next step is to reveal the cause of the deficiency,
which, as described above, may be low intake, poor
absorption, destruction of the coenzyme forms by nitrous
oxide, transcobalamin deficiency, etc. The predominant
cause of cobalamin deficiency is poor absorption. This is
the case in genuine pernicious anemia, which also occurs
in children. The patients do not secrete gastric intrinsic
factor because of atrophic gastritis, which is accompanied
by antibodies against parietal cells and gastric intrinsic
factor; presence of the latter antibodies is highly sugges-
tive of pernicious anemia. Intrinsic factor may also be
measured in gastric juice and found to be lacking, some-
times congenitally. In other kinds of cobalamin malab-
sorption (including IGS) it is present.
Until recently, absorption tests with radiocobalt-labeled
cobalamin were routinely used to study patients with
megaloblastic anemia and related conditions. Schilling's
urinary excretion technique was the most popular method
[28]. A small standard dose (usually 1 µg) of radiocobala-
min is first given by mouth. This is followed by a
parenteral injection of a large dose (usually 1 mg) of non-
radioactive cobalamin. Most of this "flushing dose" can-
not be retained and is excreted in the urine together with
the radioactivity, the amount of which reflects the quan-
tity of radiocobalamin absorbed by the intestine. If the
urinary radioactivity is low, cobalamin is probably poorly
absorbed. In this case, the test is usually repeated by giving
intrinsic factor with the test dose. If this results in
increased absorption (and excretion) of radioactivity, lack
of intrinsic factor is the cause of the cobalamin malab-
sorption, i.e. the patient has pernicious anemia [28]. If the
excretion of radioactivity does not increase, this is called a
"malabsorption response". To elucidate the cause of this
response, the test may be repeated after treatment (e.g.
expulsion of tapeworm) or by giving various substances
(e.g. food, enzymes, antibiotics) orally together with the
radioactivity. As detailed in the original article describing
IGS [13], these tests allow the known causes of vitamin
B12 malabsorption to be systematically eliminated. Intrin-
sic factor activity may also be measured in this way or by
immunoassay of gastric juice. There was a period when
radioactive cobalamin was unavailable and the corre-
sponding absorption tests, including the Schilling test,
were impossible to perform. However, 57Co-labeled vita-
min can now be purchased (supplier MP Biomedicals,
29525 Fountain Parkway, Solon, OH 44139, USA [29].
The absorption of vitamin B12  from the intestine is
reflected by a rise in serum levels of the vitamin bound to
transcobalamin, 'holo-TC' following oral administration
of the vitamin. First, a standard dose of non-radioactive
cobalamin is given alone. If a sufficient increase in holo-
TC level is not obtained, the test should be repeated,
administering the vitamin bound to intrinsic factor. In
intrinsic factor deficiency, holo-TC will rise. In malab-
sorption this rise is not observed. This relatively new test
has been used successfully in the diagnosis of IGS [30].Orphanet Journal of Rare Diseases 2006, 1:17 http://www.OJRD.com/content/1/1/17
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A complicating factor is that enterocyte function is
affected by cobalamin deficiency, causing secondary mal-
absorption. In this case, absorption tests may indicate
general malabsorption and administration of intrinsic
factor may fail to increase the absorption of radioactive
cobalamin. Such tests should therefore be performed
when the deficiency state has been corrected [2,31,32].
However, postponing or repeating the tests is time-con-
suming, collection of urine cumbersome and the costs
may be high. The radiolabeled vitamin B12 absorption
tests and intrinsic factor assays are often not available.
Recently, the greatest problem has been to differentiate
between IGS and intrinsic factor-deficiency [20]. Molecu-
lar analysis of the CUBN, AMN and GIF genes may there-
fore be the diagnostic method of choice [20]. Due to the
uncertainty regarding the diagnosis, many reported cases
need to be re-evaluated and data on the frequency of
symptoms, such as proteinuria, may have to be corrected.
When found, proteinuria is strongly suggestive of IGS.
However, the incidence seems to be lower than generally
assumed. In a study on 13 Finnish cubilin-deficient
patients, we found that moderate or clearly evident pro-
teinuria was present in six of the subjects. In the patients
with proteinuria, the excretion of total protein and albu-
min, and to a lesser extent transferrin, immunoglobulin
light chains, and α1- and β2-microglobulins was
increased. The urinary excretion of the cobalamin-intrin-
sic factor receptor was low in five of the patients studied.
Light and electron microscopy of kidney biopsies revealed
no or slight and uncharacteristic changes. These minor
alterations were probably due to cobalamin deficiency
rather than to true kidney disease [6]. Similar findings
were made in a Norwegian study [7].
The cobalamin-intrinsic factor receptor is excreted in the
urine and was found to be decreased in the cubilin-defi-
cient Finnish patients [6,33]. Whether this test is useful in
diagnosing patients with the AMN mutation is unknown.
When there is reasonable evidence to suspect that the
patient suffers from IGS, a new and straightforward way to
diagnosis is mutational analysis of the appropriate genes.
If this molecular approach is unavailable, it is necessary to
resort to the series of radiovitamin B12 and other tests
described above, among which it would be advisable to
include the assay of intrinsic factor in the gastric juice.
However, as the treatment for both congenital lack of
intrinsic factor and IGF is the same, there is no risk for the
patient if one cannot distinguish between these two con-
ditions.
Treatment
As in genuine pernicious anemia, life-long treatment with
vitamin B12 is necessary for IGS. The vitamin B12 defi-
ciency is first corrected by giving intramuscular injections
of cobalamin (1 mg of hydroxocobalamin daily for 10
days). It is recommended that these injections are then
repeated once a month for the rest of the patient's life.
There are differences in opinion as to whether cyanoco-
balamin should be used to treat cobalamin deficiency.
Cyanocobalamin is usually administered first as injec-
tions and then possibly orally in large doses. If injected,
cyanocobalamin is poorly retained and some patients
may fail to respond or even have side effects such as mus-
cular pains, possibly due to inability to process cyanide.
There is thus a case for withdrawal of this drug [34]. Oral
treatment is based on the finding that when large doses of
vitamin B12  are given orally, sufficient amounts are
absorbed, even in the absence of intrinsic factor. Success-
ful treatment of IGS with 1 mg of vitamin B12, orally
administered at 2-week intervals, has been reported [30].
However, in early studies on Finnish patients, the absorp-
tion of milligram doses of dilute radioactive cobalamin
was lower than that in pernicious anemia patients
[31,32]. In view of the accumulating evidence that sub-
clinical deficiency of cobalamin may contribute to the
development of atherosclerosis, dementia and osteoporo-
sis [3-5] and considering that cobalamin is non-toxic, it is
suggested that patients receive a higher dose of cobalamin
than necessary, rather than an insufficient dose.
The condition is rare, the first symptoms are vague and in
theory, the deficiency may cause serious damage, espe-
cially to the brain. Early diagnosis is therefore important.
Genetic counseling
The disease is transmitted as an autosomal recessive trait.
Therefore, the relatives of the patients should be told
about the disease and advised to mention the possibility
of the disease to their physician.
Prognosis
When sufficient amounts of vitamin B12 are supplied, the
prognosis is excellent. The first cases have been observed
for almost 50 years. When the deficiency state has been
corrected, the only nutrient to be malabsorbed is vitamin
B12; the proteinuria also persists. The proteinuria does not
increase with time and kidney function does not deterio-
rate. The patient (or the parents) should be warned not to
stop the treatment even though symptoms seem not to
reappear immediately following cessation of therapy.
Unresolved questions
The putative additional genes causing IGS should be iden-
tified and the safety of oral treatment needs to be better
documented. Hopefully, the genetic tests will become eas-
ily available. The structures and modes of action of thePublish with BioMed Central    and   every 
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intestinal cobalamin-intrinsic factor receptor and the
tubular protein-receptor need to be elucidated.
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